Biopharmaceutical company AbbVie (NYSE:ABBV) said on Monday that it plans to develop and commercialize SHP2 inhibitors that target a key node in cancer and immune cells under a global, strategic collaboration with Jacobio Pharmaceuticals, subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

The company added that SHP2 is an important protein mediator of cellular signaling through RAS/MAP kinase pathway. Many tumours have genetic mutations, driving abnormal cancer cell growth which relies on SHP2 activity. The inhibition of SHP2 is believed to have dual effects by potentially reducing cancer cell growth and modulating immune responses to generate anti-tumour activities.

Additionally, Jacobio's early clinical stage SHP2 assets, JAB-3068 and JAB-3312, are oral small molecules designed to specifically inhibit SHP2 activity. It will continue to conduct its early global clinical trials,with AbbVie covering R&D expenses.

Pursuant to the agreement, AbbVie will receive an exclusive license to the SHP2 portfolio as well as assume global development and commercialization responsibilities.

Upon completion, Jacobio has an option, exercisable before the initiation of registrational trials, to exclusively develop and commercialize the SHP2 programme in mainland China, Hong Kong and Macau.